Samsung Biologics announced that its revenue for the third quarter reached 1.49 trillion won, with an operating profit of 640.1 billion won. This marks a 19% increase in revenue and a 1% rise in operating profit compared to the same period last year.
The growth is attributed to the continued full operation of its first through fourth plants, ramp-up of the fifth plant, and revenue recognition from the production facility in Rockville, USA, acquired in March of this year. Revenue increased by 18.5% and operating profit rose by 1.0% year-on-year.
For the year-to-date, cumulative revenue and operating profit stand at 4.0684 trillion won and 1.8073 trillion won, respectively, reflecting increases of 24.4% and 17.3% compared to the previous year.
Additionally, Samsung Biologics has raised its annual revenue growth guidance from a range of 15% to 20% to a target of 20% growth. The company explained that this adjustment considers solid revenue growth based on full operation of the first through fourth plants, revenue recognition from batches for certification at the fifth plant in the second half, and stabilization of commercial production at the Rockville facility.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.